SEARCH

SEARCH BY CITATION

References

  • 1
    Waal HJ. Propranolol-induced depression. Br Med J 1967; ii: 50.
  • 2
    Avorn J, Everitt DE, Weiss S. Increased antidepressant use in patients prescribed beta-blockers. JAMA 1986; 255: 357360.
  • 3
    Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996; 7: 478484.
  • 4
    Gerstman BB, Jolson HM, Bauer M, Cho P, Livingston JM, Platt R. The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiol 1996; 49: 809815.
  • 5
    Bright RA & Everitt DE. Beta-blockers and depression. Evidence against an association. JAMA 1992; 267: 17831787.
  • 6
    Thiessen BQ, Wallace SM, Blackburn JL, Wilson TW, Bergman U. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch Intern Med 1990; 150: 22862290.
  • 7
    Patten SB. Propranolol and depression: evidence from antihypertensive trials. Can J Psychiatry 1990; 35: 257259.
  • 8
    Ried LD, McFarland BH, Johnson RE, Brody KK. Beta-blockers and depression: the more the murkier? Ann Pharmacother 1998; 32: 699708.
  • 9
    Biriell C & McEwen Sanz E. Depression associated with diltiazem. Br Med J 1989; 299: 796.
  • 10
    Dassylva B. Verapamil may cause depression. Can J Psychiatry 1993; 38: 299300.
  • 11
    Hullett FJ, Potkin SG, Levy AB, Ciasca R. Depression associated with nifedipine-induced calcium channel blockade. Am J Psychiatry 1988; 145: 12771279.
  • 12
    Lindberg G, Bingefors K, Ranstam K, Rastam L, Melander A. Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study. Br Med J 1998; 316: 741745.
  • 13
    Gasse C, Derby LE, Vasilakis C, Jick H. Risk of suicide among users of calcium channel blockers: population based, nested case-control study. Br Med J 2000; 320: 1251.
  • 14
    Patten SB, Williams JV, Love EJ. Case-control studies of cardiovascular medications as risk factors for clinically diagnosed depressive disorders in a hospitalized population. Can J Psychiatry 1996; 41: 469476.
  • 15
    Olsen JH, Sørensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997; 29: 10911094.
  • 16
    Capellá D. Descriptive tools and analysis. In Drug Utilization Studies: Methods and Uses ed. DukesMNG. Copenhagen: WHO Regional Publications, 1993: 5578. (European Series no. 45).
  • 17
    Svendsen TL. Beta-receptorblokkerende midler. In Lægemiddelkataloget. Copenhagen: Dansk Lægemiddel Information eds KristensenMB, FriisH, RassingMR. 1998: 179183.
  • 18
    Lægeforeningens Medicinfortegnelse Copenhagen. Lægeforeningens Forlag, 1994.
  • 19
    Sundhedsstyrelsen. Causes of Death in Denmark 1996. Munksgårds Forlag, 1996.
  • 20
    Rothman KJ, Boice JD Jr. , DC. Government Printing Office. (DHHS publication no. (NIH) 79–1649), 1979.
  • 21
    Beers MH & Passman LJ. Antihypertensive medications and depression. Drugs 1990; 40: 792799.
  • 22
    Conant J, Engler R, Janowsky D, Maisel A, Gilpin E, LeWinter M. Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility. J Cardiovasc Pharmacol 1989; 13: 656661.
  • 23
    Kyvik KO, Stenager EN, Green A, Svendsen A. Suicides in men with IDDM. Diabetes Care 1994; 17: 210212.
  • 24
    Breslau N. Migraine, suicidal ideation, and suicide attempts. Neurology 1992; 42: 392395.
  • 25
    Edwards JG. Depression, antidepressants, and accidents. Br Med J 1995; 311: 887888.
  • 26
    Lavorato DH & Patten SC. Antihypertensive medications and depression, an historical perspective. Pharmacoepidemiol Drug Safety 1999; 8: 355359.